Related Experiment Video
Updated: Sep 3, 2025
07:47
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.6K
Does Myasthenia Gravis Affect Long-Term Survival in Thymic Carcinomas? An ESTS Database Analysis
Filippo Lococo1,2, Dania Nachira1,2, Marco Chiappetta2
1Thoracic Surgey, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Diagnostics (Basel, Switzerland)
|July 27, 2022
Summary
Myasthenia gravis (MG) affects about 10% of thymic carcinoma patients. This study found MG presence did not significantly impact long-term survival in surgically treated thymic carcinoma cases.
Area of Science:
- Oncology
- Neurology
- Thoracic Surgery
Background:
- Thymic carcinoma is a rare, aggressive cancer with poor outcomes.
- It can sometimes occur alongside myasthenia gravis (MG).
Purpose of the Study:
- To determine the incidence of MG in a surgical thymic carcinoma cohort.
- To assess the impact of MG on long-term survival after surgery for thymic carcinoma.
Main Methods:
- Analysis of prospectively collected data from the European Society of Thoracic Surgeons (ESTS) database.
- Inclusion of clinical, pathological, and survival data from 203 thymic carcinoma patients.
- Statistical analysis to compare outcomes between patients with and without MG.
Main Results:
- Myasthenia gravis was identified in 10.8% of thymic carcinoma patients.
- MG was more prevalent in older (>60 years) and male patients.
- Long-term survival rates (3, 5, and 10 years) were 79%, 75%, and 63%, respectively; MG did not significantly affect these rates.
Conclusions:
- Myasthenia gravis is present in approximately 10% of thymic carcinoma cases.
- Surgical treatment of thymic carcinoma appears to yield similar long-term prognoses regardless of MG status.
- Factors like age, gender, tumor stage, and radiotherapy influenced survival more than MG.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
01:15Myasthenia Gravis: Diagnostic Tests
1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K
01:21Cancer Survival Analysis
437
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
437